Evidence map›Paper›PMID 40802280›Full record

ArticleFuture science OA2025

Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy.

Pei Xun, Jiabao Zong, Shenglan Li, Wenbin Li

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Pei XunDepartment of Neuro-Oncology , Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiabao ZongDepartment of Oncology, Beijing Daxing District People's Hospital, Beijing, China.
Shenglan LiDepartment of Neuro-Oncology , Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wenbin LiDepartment of Neuro-Oncology , Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate whether liposomal honokiol enhances the anti-tumor effect of bevacizumab (BEV) in glioblastoma (GBM) and explore its underlying mechanism. MATERIALS &

methodsA U87 cell xenograft model in nude mice was used, with groups: model (M), M + liposomal honokiol (Lip-HNK), M + BEV, and M + Lip-HNK + BEV. Tumor volume, body weight, serum levels of VEGF, VEGFR, TNF-α, and Caspase-3, and expressions of autophagy-related (Beclin-1, LC3) and UPR-related (IRE1, GRP78) molecules in tumor tissues were detected.

resultsCompared with monotherapy, the combination of Lip-HNK and BEV significantly reduced tumor volume and tumor index, decreased serum levels of VEGF, VEGFR, and TNF-α, while increasing serum caspase-3. Further mechanistic studies showed that the combination of Lip-HNK and BEV significantly reduced the expression of Beclin-1, LC3, IRE1, and GRP78 in tumors.

conclusionsLip-HNK may promote the anti-GBM effect of BEV by inhibiting autophagy mediated by the UPR response.

Indexed as

autophagybevacizumabglioblastomaLiposomal honokiolUPR sensor

Identifiers

PMID40802280
PMCPMC12351733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.